Biohaven (BHVN) Following Its Court Win Still Looks Cheap Against Fair Value

Biohaven (BHVN) is back in focus after a federal jury found that Avilar Therapeutics and RA Capital Management willfully misappropriated trade secrets tied to its licensed MODA protein degradation platform, awarding damages to Biohaven and Yale University.

See our latest analysis for Biohaven.

Following the verdict, Biohaven's share price has eased in the very short term, with a 1-day share price return of 5.10% decline and a 7-day share price return of 11.22% decline. However, the 90-day share price return of 49.67% and year to date share price return of 27.03% suggest momentum has built over recent months despite a 3-year total shareholder return of 29.92% decline.

If this kind of legal and pipeline driven story has your attention, it can also be useful to widen your search using a curated list of 40 healthcare AI stocks.

After the legal win and sharp move in Biohaven’s share price, the stock still trades well below both analyst targets and some intrinsic value estimates. So where might fair value actually sit within that wide range?

DCF suggests a wide gap between Biohaven's price and fair value

The SWS DCF model estimates a fair value of $61.24 for Biohaven, compared with the recent close at $13.77, which indicates a very large implied discount.

The model works by projecting Biohaven's future cash flows and then discounting them back to today using a required return. That gives a single present value estimate for the stock based on those cash flow forecasts.

For a company like Biohaven, which is still loss making and focused on clinical development, a DCF framework leans heavily on assumptions about future revenue ramp up, margins and funding needs rather than current earnings.

Investors weighing this output may want to compare the DCF view with analyst targets, the current balance sheet position and the pipeline progress that will ultimately need to support those future cash flows.

Look into how the SWS DCF model arrives at its fair value.

Result: DCF fair value of $61.24 (model suggests the stock is trading below this estimate)

However, Biohaven still faces key risks, including its lack of current revenue and the possibility that clinical trial outcomes or regulatory decisions may fall short of expectations.

Find out about the key risks to this Biohaven narrative.

Another view on Biohaven's valuation

While the SWS DCF model suggests Biohaven trades at a steep discount to its estimated fair value, the market is sending a very different signal when you look at the P/B ratio. Biohaven trades at about 16x book value, compared with 2.4x for the wider US biotech industry and 3.1x for its peer group.

That gap is very wide. It indicates investors are paying a much higher price for each dollar of net assets than is typical in this space. This raises questions about how much future success is already reflected in the current share price.

See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Biohaven for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on Biohaven's valuation and outlook can feel hard to balance. Make time to review the full picture on risks and upside before markets move again and weigh the 2 key rewards and 5 important warning signs

Looking for more investment ideas beyond Biohaven?

If Biohaven has sharpened your interest in stock selection, do not stop here. The next opportunities you shortlist today could shape your portfolio for years.

• Target potential mispricings by reviewing 49 high quality undervalued stocks that combine stronger fundamentals with room for the market to reassess expectations.
• Strengthen your income stream by assessing 8 dividend fortresses that focus on higher yields backed by more established cash generation.
• Dial down portfolio stress by filtering for 83 resilient stocks with low risk scores that aim to balance return potential with more resilient financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com